Beiersdorf and Rubedo join forces to target cellular senescence

Beiersdorf and Rubedo Life Science have entered into a multi-year strategic partnership to develop a breakthrough anti-aging solution for the global face care market. The German beauty giant additionally joins Rubedo as strategic investor, having participated in its recently closed Series A financing round through its Oscar & Paul Corporate Venture Capital Fund. Rubedo Life Science is a California-headquartered biotech company with an expertise in the development of solutions targeting cellular senescence.

Innovative antiaging substances

The partnership revolves around the exploration of novel compounds derived from Rubedo’s extensive research programs, specifically targeting cellular senescence.

Senescent cells [Latin senescere = to grow old, to age] accumulate with age and cause inflammation, which may contribute to age-related skin changes and pathologies. These compounds will be sourced from Rubedo’s topical dermatology program, which have senolytic and anti-inflammatory properties.

As part of this partnership, Beiersdorf will conduct in vitro and in silico studies and conduct stringent assessments of Rubedo’s candidate compounds. This collaboration will result in in vivo human studies, aimed at validating the effectiveness of the selected substances in cosmetic skin care formulations.

Our mission is to define the future of skin care through breakthrough innovation,” commented Beiersdorf CEO Vincent Warnery. “By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skincare.

Dr. Gitta Neufang, Beiersdorf Corporate Senior Vice President Global R&D added: “We see enormous potential in the very dynamic research field of cellular senescence to develop superior solutions for skin rejuvenation.

By combining Rubedo’s expertise in cellular senescence with Beiersdorf’s expertise in skin care innovation, this partnership may revolutionize the landscape of skin care products, offering consumers new solutions that treat cellular aging for healthy and youthful-looking skin,” concluded Marco Quarta, CEO of Rubedo Life Sciences.

Beiersdorf’s brand portfolio includes Nivea, Eucerin and La Prairie, among others. [The company recently announced the development of a newly patented ingredient. Trademarked by Beiersdorf as Glycostop, the new NAHP [N-acetyl-L-hydroxyproline] targets sugar-induced skin ageing and wrinkle formation, known as glycation.->,23765]

Source link

About The Author

Scroll to Top